RxDoctor Payments Data

Charles McCall, MD

Urology · Columbus, GANPI 1316969561

Payments from drug & device makers

$5,895in general payments, 2019–2025

Across 279 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$752
  • Astellas Pharma US Inc$739
  • Endo Pharmaceuticals Inc.$597
  • Sumitomo Pharma America, Inc.$465
  • Johnson & Johnson$350
  • Boston Scientific$333
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$5,68696%
  • Education$2094%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,895 in reported general payments places this provider in the 60th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$210,959
Medicare patients
675
Services billed
23,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron146$97,564
MyrbetriqMirabegron26$22,984
Testosterone11$4,468
Tadalafil31$2,417
Tamsulosin Hcl250$2,241
Finasteride108$1,168
Testosterone Cypionate21$870
Alfuzosin Hcl ErAlfuzosin Hcl22$604
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst27$578
Sildenafil Citrate59$478
Oxybutynin Chloride ErOxybutynin Chloride36$450
Desmopressin Acetate14$428
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen42$220
Ciprofloxacin Hcl51$203
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim16$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$465$97,564146 claims
Astellas Pharma US IncMyrbetriq$739$22,98426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 369 urology providers in Georgia.

Other urology in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →